Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer

Breast Cancer Research and Treatment

Volumn 123, Issue 1, 2010, Pages 197-202

  Qi, Meng ^a   Li, Jin Feng ^a   Xie, Yun Tao ^a   Lu, Ai Ping ^a   Lin, Ben Yao ^a   Ouyang, Tao ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Breast cancer; Efficacy; Paclitaxel; Primary chemotherapy; Schedule; Toxicity

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; PACLITAXEL; PIRARUBICIN; ANTINEOPLASTIC AGENT; DOXORUBICIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; ECHOMAMMOGRAPHY; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY DELAY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BREAST NEOPLASMS; DRUG ADMINISTRATION; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; ROC CURVE; TREATMENT OUTCOME;

EID: 77955773253     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1000-2     Document Type: Article

References (15)

1. HD Bear 1998 Indications for neoadjuvant chemotherapy for breast cancer Semin Oncol 25 (2 Suppl 3) 3 12 1:STN:280:DyaK1c3islehsQ%3D%3D 9566201
2. GN Hortobagyi 1990 Comprehensive management of locally advanced breast cancer Cancer 66 Suppl 6 1387 1391 10.1002/1097-0142(19900915)66:14+<1387:: AID-CNCR2820661414>3.0.CO;2-I 1:STN:280:DyaK3czotFKksQ%3D%3D 2205369
3. Priya Rastogi StewartJ Anderson HarryD Bear,, et al. 2008 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 778 785 10.1200/JCO.2007.15.0235 18258986 (Pubitemid 351264391)
4. JA Van der Hage CJ van de Velde JP Julien,, et al. 2001 Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 4224 4237 11709566
5. IC Henderson DA Berry GD Demetri,, et al. 2003 Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 6 976 983 10.1200/JCO.2003.02.063 1:CAS:528: DC%2BD2cXpsVGqs7c%3D 12637460 (Pubitemid 46594124)
6. J Nabholtz T Pienkowski J Mackey,, et al. 2002 Phase III trial comparing TAC(docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study (abstract) Proc Am Soc Clin Oncol 21 1 36a
7. IC Smith SD Heys AW Hutcheon,, et al. 2002 Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 1456 1466 10.1200/JCO.20.6.1456 1:CAS:528:DC%2BD38XivFeisbg%3D 11896092 (Pubitemid 34260523)
8. Seidman AD, Berry D, Cirrincione C, et al (2004) CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol 22(Suppl 6s) (abstract)
9. A Goldhirsch JH Glick RD Gelber,, et al. 2005 Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 1569 1583 10.1093/annonc/mdi326 1:STN:280: DC%2BD2MvpvFKhsA%3D%3D 16148022 (Pubitemid 41511089)
10. WT Yang MJ Dryden K Gwyn,, et al. 2006 Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy Radiology 239 52 60 10.1148/radiol.2391050083 16484353
11. KN Ogston ID Miller S Payne,, et al. 2003 A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival The Breast 12 320 327 10.1016/S0960-9776(03)00106-1 14659147 (Pubitemid 37322062)
12. C Liedtke C Mazouni KR Hess,, et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 8 1275 1281 10.1200/JCO.2007.14.4147 18250347
13. MC Green AU Buzdar T Smith,, et al. 2005 Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J Clin Oncol 23 5983 5992 10.1200/JCO.2005.06.232 1:CAS:528:DC%2BD2MXhtVKgtb3O 16087943
14. AD Seidman D Berry C Cirrincione,, et al. 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors, random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer, Leukemia Group B protocol 9840 J Clin Oncol 26 10 1642 1649 10.1200/JCO.2007.11.6699 1:CAS:528:DC%2BD1cXltlWhsr0%3D 18375893
15. JA Sparano M Wang S Martino,, et al. 2008 Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 1663 1671 10.1056/NEJMoa0707056 1:CAS:528:DC%2BD1cXkslCitLk%3D 18420499 (Pubitemid 351549913)